Study S000080

A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01296412
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 653
Start: 2011-03-11
Primary completion: 2012-02-29
Lead sponsor: Merck Sharp & Dohme LLC
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:sitagliptin; DRUG:liraglutide; DRUG:glimepiride; DRUG:metformin
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (A1C) [Baseline and Week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026295	Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Charbonnel B, Diabetologia	2013	Randomized trial	PMID 23604551 DOI	cites ClinicalTrials.gov:NCT01296412; registry reference DERIVED:23604551